scholarly journals Pengaruh durasi senam diabetes pada penurunan glukosa darah penderita diabetes mellitus tipe II

2018 ◽  
Vol 15 (2) ◽  
pp. 37
Author(s):  
Weni Kurdanti ◽  
Tri Mei Khasana
Keyword(s):  
Type 2 Diabetes ◽  
Blood Glucose ◽  
Aerobic Exercise ◽  
Blood Sugar ◽  
Significant Difference ◽  
Before And After ◽  
Post Test ◽  
Group A ◽  
Group B

Background: The management of DM focused on four pillars: education, nutrition therapy, physical exercise, and pharmacological interventions. In type 2 diabetes, physical activity functions primarily in controlling diabetes.Objective: This study aims to determine the effect of differences in the duration of aerobic exercise on blood glucose levels.Method: This was quasi-experimental research with pre-post test design. A total of 24 respondents with type 2 diabetes were divided into two groups consisting of groups A that received aerobic exercise with a duration of 30 minutes and group B received aerobic exercise with a duration of 60 minutes for 6 weeks and frequency of exercise 3 times each week. Statistical tests use paired t-tests and independent t-tests.Results: The mean post-test blood sugar level based on HbA1c measurements in group A was 7.92±1.56% while group B was 7.13±0.99%. Mean pre-test - post-test blood sugar levels in the two groups were significantly different (p<0.05). Aerobic exercise for 6 weeks with a frequency of 3 times each week can reduce HbA1c by -2.5±0.96% in group A while group B increased by 0.02±0.29%. There is a significant difference in HbA1c before and after 6 weeks of aerobic exercise between two groups (p=0.021).Conclusion: Aerobic exercise with a duration of 30 minutes for 6 weeks 3 times each week can reduce blood glucose (HbA1c) by -2.5±0.96% while the group duration of aerobic exercise 60 minutes an increase of 0.02±0.29%. There is a significant difference in HbA1c before and after 6 weeks of aerobic exercise between the two groups.

scholarly journals EFFECT OF ALPHA LIPOIC ACID IN TREATMENT OF TYPE 2 DIABETES

2017 ◽  
Vol 10 (8) ◽  
pp. 204 ◽  
Author(s):  
Priyambada Panda ◽  
Sitansu Kumar Panda ◽  
Tapaswini Mishra
Keyword(s):  
Type 2 Diabetes ◽  
Lipid Profile ◽  
Blood Sugar ◽  
Lipoic Acid ◽  
Glycosylated Hemoglobin ◽  
Alpha Lipoic Acid ◽  
Before And After ◽  
Group A ◽  
Group B

  Objective: Antioxidant probably can prevent the progression and complications of Type 2 diabetes mellitus (T2DM). Due to effectiveness of alpha lipoic acid (ALA) as an antioxidant, this study was done in T2DM patients to evaluate the effect of ALA on their diabetic status, lipid profile, and oxidative stress (OS) status.Methods: A total of 35 patients with diabetes were selected randomly who were under insulin treatment mainly and grouped as Group “A.” Another age- and sex-matched healthy controls selected grouped as “B.” Both groups supplemented with ALA (300 mg/day) for 6 months continuously. All parameters were tested before and after the supplementation.Results: There was a significant decrease in fasting blood sugar from 161 to 122 mg/dl in Group “A” and from 98 to 90 mg/dl in Group “B.” Postprandial blood sugar (PPBS) and glycosylated hemoglobin (HbA1c) levels also significantly decreased from 211 to 158 mg/dl and 8.81% to 7.2%, respectively, in Group “A.” PPBS levels significantly decreased from 130 to 124 mg/dl in Group “B,” but HbA1c% decreased insignificantly from 5.26% to 5.24% in Group “B.” Lipid profile parameters decreased in both groups except triglyceride level, which show insignificant relation in Group “B.” OS marker malondialdehyde significantly decreased from 1.967 to 1.592 nm/ml in Group “A” and from 0.613 to 0.472 nm/ml in Group “B.” Plasma antioxidant glutathione shows a significant increase in both groups from 2.117 to 2.405 μmol/L in Group “A” and from 2.631 to 2.811 μmol/L in Group “B.” Plasma nitric oxide also shows significant increase in both groups from 1.712 to 1.990 μmol/L and from 2.139 to 2.318 μmol/L, respectively.Conclusion: Therefore, ALA is a potent antioxidant and can be used against oxidative injury associate with T2DM.

scholarly journals Clinical appraisal of Lodhradi Kashaya on type 2 diabetes mellitus patients

2017 ◽  
Vol 4 (1) ◽  
pp. 58
Author(s):  
Varun K. Singh ◽  
K. R. C. Reddy
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Blood Glucose ◽  
Dosage Form ◽  
Dose Group ◽  
Group A ◽  
Group B

<p class="abstract"><strong>Background:</strong> <span lang="EN-IN">Lodhradi Kashaya (LKSD) is basically ayurvedic kwath dosage form, described as Madhumehajeet (winner of diabetes mellitus) in ayurvedic classics Basavarajeeyam and the same formulation in Vaidya Chintamani and Charaka Samhita too. The aim of this study was to assess prospectively the drug’s ability in management of type 2 diabetes. </span></p><p class="abstract"><strong>Methods:</strong> <span lang="EN-IN">Total 31 patients were taken following the guideline mention in CCRAS protocol for diabetes mellitus research. They are divided into two groups, group A and B, given LKSD 4 g &amp; 2 g TDS respectively for three-month follow up. They are investigated against their blood glucose, HbA1C and liver profile tests. Patients were also investigated for subjective parameters viz polyurea, polyphagia, exhaustion and constipation and their response has also been noted regarding palatability acceptance and ease of administration.</span></p><p class="abstract"><strong>Results:</strong> <span lang="EN-IN">Patients has responded positively for formulation. Decrease in FBS and PPBS were found highly significant (P ˂ 0.001) in both groups but more in higher dose (group A). Decrease in HbA1C is also found highly significant in both groups. In LFT, SGOT level were also decreased more in group B in comparison to group A, and it is significant (P = 0.017 and 0.002). SGPT level were also decreased more in group B in comparison to group A, and it is significant in group B (P= 0.085 and 0.002).  </span></p><p class="abstract"><strong>Conclusions:</strong> LKSD is having astringent taste due to tannins and phenols in it. It was found significant not only in controlling blood sugar but also in management of other factors related to diabetes mellitus.</p>

scholarly journals Effectiveness of the Family Portal Function on the Lilly Connected Care Program (LCCP) for Patients With Type 2 Diabetes: Retrospective Cohort Study With Propensity Score Matching

10.2196/25122 ◽  
2021 ◽  
Vol 9 (2) ◽  
pp. e25122
Author(s):  
Yiyu Zhang ◽  
Chaoyuan Liu ◽  
Shuoming Luo ◽  
Jin Huang ◽  
Yuxin Yang ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Blood Glucose ◽  
Fasting Blood Glucose ◽  
Postprandial Blood Glucose ◽  
Self Monitoring ◽  
The Family ◽  
Group A ◽  
Group B ◽  
Education Courses

Background Diabetes is a major health concern worldwide. Family member engagement in diabetes self-management education programs can improve patients’ diabetes management. However, there is limited evidence that the family portal on diabetes management apps is effective in the glycemic control of patients with diabetes. Objective We aimed to evaluate the effectiveness of family support through the family portal function on Lilly Connected Care Program (LCCP) platform. Methods This retrospective cohort study included patients with type 2 diabetes recruited to the LCCP platform from September 1, 2018, to August 31, 2019. Propensity score matching was used to match family (group A) and non–family (group B) portal use groups with similar baseline characteristics. The patients were followed up with for 12 weeks. The main objectives were differences in mean fasting blood glucose, proportion of patients achieving fasting blood glucose target <7mmol/L, mean postprandial blood glucose, proportion of patients achieving postprandial blood glucose target <10mmol/L, proportion of patients achieving both fasting blood glucose <7mmol/L and postprandial blood glucose <10mmol/L, self-monitoring of blood glucose frequency at week 12 and the number of diabetes education courses patients completed during the 12 weeks. Moreover, logistic regression analysis was used to explore the baseline factors which may be associated with the use of family portal, and odds ratios with 95% confidence intervals were calculated. Results A total of 6582 adult patients (aged ≥18 years) with type 2 diabetes who were receiving insulin therapy were enrolled in the study. Overall, 6.1% (402/6582) of the patients chose to engage their family members to use the family portal. Two groups of 394 patients were well-matched regarding baseline characteristics. After matching, mean fasting blood glucose and postprandial blood glucose at week 12 were significantly lower in group A than in group B (fasting blood glucose: 7.12 mmol/L, SD 1.70 vs 7.42 mmol/L, SD 1.88, respectively, P=.02; postprandial blood glucose: 8.56 mmol/L, SD 2.51 vs 9.10 mmol/L, SD 2.69, respectively, P=.002). When comparing group A to group B, the proportion of patients achieving both fasting blood glucose <7mmol and postprandial blood glucose <10mmol/L at week 12 (46.8% vs 39.4%, respectively, P=.04), self-monitoring of blood glucose frequency at week 12 (8.92 times per week, SD 6.77 vs 8.02 times per week, SD 5.97, respectively, P=.05) and number of diabetes education courses completed in 12 weeks (23.00, IQR9.00-38.00 vs 15.00, IQR 4.00-36.00, respectively, P<.001) was higher. Additionally, multivariate logistic regression analysis showed that higher age (OR=0.987, 95% CI 0.978-0.996, P=.006) and higher baseline fasting blood glucose (OR=0.914, 95% CI 0.859-0.972, P=.004) were correlated with less use of the family portal function, while increased baseline self-monitoring of blood glucose frequency (OR=1.022, 95% CI 1.012-1.032], P<.001) as well as increased education courses (OR=1.026, 95% CI 1.015-1.036, P<.001) were associated with more use of the family portal function. Conclusions Family support through the LCCP family portal is effective for glycemic control and self-management behavior improvement in type 2 diabetes patients.

Impact of aerobic exercise against general mobilisation exercise on exercise tolerance among type 2 diabetes mellitus

2021 ◽  
pp. 1-4
Author(s):  
I.V. Chandrashekaran ◽  
N. Ravi ◽  
B. Srinivasagopalane
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Aerobic Exercise ◽  
Exercise Tolerance ◽  
Walk Test ◽  
Significant Difference ◽  
Group B ◽  
Minute Walk

The objective of the study was to compare general mobilisation exercises with aerobic exercises on exercise tolerance in subjects with type 2 diabetes mellitus. Thirty type 2 diabetes mellitus subjects of both the genders in age-group between 35 and 60 years were divided into 2 groups (A and B) and were subjected to a 6-minute walk test pre- and post-training exercise. Group A participants were subjected to general mobilisation exercises and group B to aerobic exercises. The six-minute walk test between the two groups (A and B) was statistically different at P=0.03. Our study showed a significant difference in improvement of exercise tolerance in Group-B subjects, who underwent aerobic exercise. In conclusion, aerobic exercise is a better health intervention in the improvement of exercise tolerance among type 2 diabetes mellitus subjects, which could improve their cardio-respiratory fitness and thereby prevent further cardiovascular complications and improve their well-being.

scholarly journals PPAR-αAgonist Fenofibrate Decreased Serum Irisin Levels in Type 2 Diabetes Patients with Hypertriglyceridemia

PPAR Research ◽  
2015 ◽  
Vol 2015 ◽  
pp. 1-8 ◽  
Author(s):  
Xiaomeng Feng ◽  
Xia Gao ◽  
Yumei Jia ◽  
Heng Zhang ◽  
Qingrong Pan ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Blood Glucose ◽  
High Density Lipoprotein ◽  
Metabolic Disorders ◽  
Fasting Blood Glucose ◽  
Density Lipoprotein ◽  
Group A ◽  
Group B ◽  
Diabetes Patients

Irisin is related to insulin resistance and metabolic disorders. The physiologic effects of irisin are partially mediated through peroxisome proliferator-activated receptor-α(PPAR-α). We investigated the effect of fenofibrate, a PPAR-αagonist, on serum irisin in type 2 diabetes patients with hypertriglyceridemia. This study evaluated cross-sectional and interventional studies of 25 type 2 diabetes patients with hypertriglyceridemia (group A) and 40 controls (group B). Group A was treated with fenofibrate (200 mg/day) for 8 weeks. Serum irisin and clinical characteristics were examined. Serum irisin was significantly higher in group A compared with group B (45.15±10.48versus35.38±9.97 ng/ml,P<0.001) and correlated with body mass index (r=0.314,P=0.011), fasting blood glucose (r=0.399,P=0.001), total cholesterol (r=0.256,P=0.040), and high-density lipoprotein cholesterol (r=0.247,P=0.047). In multiple regression analysis after controlling for confounders, only fasting blood glucose (β=5.615,P<0.001) and high-density lipoprotein cholesterol (β=19.483,P<0.001) were independently related to serum irisin. After 8 weeks of fenofibrate treatment, serum irisin significantly decreased in group A compared with baseline (45.15±10.48versus38.74±12.54 ng/ml,P=0.011). Conclusively, fenofibrate decreased serum irisin in type 2 diabetes patients with hypertriglyceridemia, indicating that PPAR-αagonists may protect against metabolic disorders by improving irisin resistance.

scholarly journals The Effect of Bread Enriched With Portulaca Oleracea on Metabolic Control Indices in Patients With Type 2 Diabetes: a Parallel Randomized Clinical Trial

2021 ◽  
Author(s):  
Mehri Delvarianzadeh ◽  
Abdorreza Mohammadi Nafchi ◽  
Leila Nouri ◽  
Ahmad Khosravi ◽  
Aisa Bahar ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Clinical Trial ◽  
Metabolic Control ◽  
Blood Sugar ◽  
Density Lipoprotein ◽  
Portulaca Oleracea ◽  
Significant Difference ◽  
Before And After ◽  
The Difference

Abstract Background: Diabetes is the most common chronic disease worldwide. Some herbs are used to control diabetes. Portulaca Oleracea is a type of plant that has essential fatty acid-rich leaves. Objectives: This study aimed to evaluate the effect of bread enriched with Portulaca Oleracea on metabolic control indices in patients with type 2.Methods: This parallel randomized controlled clinical trial was conducted on 104 patients with type 2 diabetes. Participants received bulk bread containing 10% Portulaca powder for 4 weeks (intervention group), the control group used their normal daily bread. At baseline and end of the study a 12 hours fasting and 2 hours later blood sample were collected to quantify plasma glucose levels and lipid profiles. The effectiveness of the intervention method was compared with the difference between the mean before and after the intervention (change score) in the two groups using t-test.Results: The results showed that after the intervention, a significant difference was found between Fasting blood sugar, cholesterol and high-density lipoprotein variables in intervention groups, but could not affect serum low-density lipoprotein, triglyceride levels, blood sugar and Glycated hemoglobin(HbA1C) It should be noted that the difference between the means of the two groups before and after the intervention indicates that there is a significant difference between the other groups except HbA1C. Conclusions: consumption of bread enriched with portulaca oleracea did have a significant impact on metabolic indices of diabetes and improvement lipid profile. It is recommended to use bread enriched with portulaca oleracea powder, areas where the staple food is bread.Trial registration in the Iranian clinical trial system with the code IRCT2011030309006010N1.

scholarly journals Analysis on the Effect of Individualized Aerobic Exercise Intervention for Teenagers with Type 2 Diabetes

2015 ◽  
Vol 9 (1) ◽  
pp. 262-265
Author(s):  
Zhao Chun-qi
Keyword(s):  
Type 2 Diabetes ◽  
Blood Glucose ◽  
Aerobic Exercise ◽  
Exercise Intervention ◽  
Density Lipoprotein ◽  
Effective Control ◽  
C Peptide ◽  
Metabolic Equivalents ◽  
Significant Difference

This study investigates the intervention effect of individualized aerobic exercise on type 2 diabetes in teenagers. 60 cases of teenager were selected with type 2 diabetes in Zhoukou Hospital of Traditional Medicine from February 2013 to February 2014 as the research object. All enrolled patients’ maximal oxygen and blood glucose fluctuation was tested, followed by individualized aerobic exercise intervention. After 6 months of intervention, the changes in patients’ indexes were compared and the effects of individualized aerobic exercise intervention were evaluated. After the intervention, the patients’ plasma triglyceride and cholesterol content were found significantly lowered than before (P < 0.05). However, there’s no significant difference between high and low-density lipoprotein (P > 0.05). Moreover, the patients’ insulin and C-peptide levels were found significantly higher than those before intervention (P < 0.05); before intervention, their blood glucose and glycated hemoglobin level were higher than normal, after intervention, they were weakened, but there’s no significant difference (P > 0.05). The maximal oxygen uptake and different intensity of metabolic equivalents were higher than before, but there’s no significant difference (P > 0.05). For teenagers with type 2 diabetes, the implementation of individualized aerobic exercise intervention could effectively improve the patients’ lipid metabolism and cardio-pulmonary function, and effectively promote the insulin and C-peptide secretion, which provides scientific basis for effective control of blood glucose.

scholarly journals SITAGLIPTIN;

2017 ◽  
Vol 24 (11) ◽  
pp. 1755-1760
Author(s):  
Zaheer Ahmed ◽  
Hassan Fareed ◽  
Muhammad Usman Musharraf
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Blood Sugar ◽  
T Test ◽  
P Value ◽  
Diabetic Patients ◽  
Group A ◽  
Group B

The objective of this stidy is to compare the mean reduction of HbA1c in patientstaking sitagliptin insulin combination with insulin alone in patients of type II Diabetes mellitus.Study Design: Randomized control trial (RCT). Setting: Medicine Department, Allied Hospital,Faisalabad. Period: August 2013 to February 2014. Methodology: Patients of both genderswith ages between 18 and 60 years having uncontrolled type 2 diabetes mellitus with HbA1ctaking insulin were included in the study while Pregnant or lactating mothers, patients withchronic liver disease and patients with renal insufficiency (creatinine >3.0mg/dl) were excludedfrom study. Patients were randomly divided into two groups (A &B) using computer generatedrandom number table. Group A was given Sitagliptin 50mg per day and dose was increasedto 100mg per day after 2 weeks if fasting blood sugar was more than 110mg/dl or 2 hourspostprandial blood sugar more than 140mg/dl. Dose of insulin in group A remained same asbefore start of study. Group B was kept on same regimen of insulin they were already taking anddose remained same. HbA1c was done at start of study and after 24 weeks. Primary outcomemeasure was mean reduction in HbA1c levels at 24 weeks from baseline. Results: 60 patientswere included in the study. Mean age was 52.7+8.43 years. 36(60%) were male and 24(40%)were female. Mean HbA1c at baseline was 8.361+0.523% in Group A on Sitagliptin-insulincombination and 8.187+0.432% in group B on insulin alone. Mean HbA1c at 24 weeks was7.767+0.428% in group A on Sitagliptin-insulin combination and 7.69+0.407% in group B oninsulin alone.Independent sample t-test was applied to change in HbA1c in Group A and Bduring 24 weeks of treatment. Mean change in HbA1c after 24 weeks in Group A was 0.600+ 0.315 and 0.49+ 0.19 in Group B after 24 weeks treatment (p-value 0.002) which is highlysignificant. Paired sample t-test was applied to HbA1c at baseline and 24 weeks of treatmentin group A and group B. There was a significant change in both groups after 24 weeks oftreatment in both groups (p-value <0 .000) which is highly significant. Chi Square test wasapplied on efficacy in group A and B. 22(73.33%) patients in group A and 14(46.67%) patientsin group B which achieved significant reduction in HbA1c. 8(26.67%) patients in group A and16(53.33%) patients in group B failed to achieve significant reduction in HbA1c. (P-value <0.032). Conclusion: It has been concluded from this study that insulin and sitagliptin-insulincombination both significantly reduce HbA1c in type 2 diabetes mellitus. However addition ofsitagliptin to uncontrolled diabetic patients already taking insulin, is more effective than insulinfor glycemic control of patients with type 2 diabetes mellitus.

scholarly journals Correlation Between Vitamin D3 and Fasting Blood Sugar in Type 2 Diabetes Mellitus Patients and Normal Individuals in a Bangladeshi Population

2020 ◽  
Vol 9 (2) ◽  
pp. 65-68
Author(s):  
Md. Tazul Islam ◽  
Miliva Mozaffor ◽  
Md. Ehsanul Islam ◽  
Heera Lal Roy
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Blood Glucose ◽  
Vitamin D3 ◽  
Fasting Blood Glucose ◽  
Group A ◽  
Group B ◽  
25 Hydroxycholecalciferol

Background and Aims: Controversies prevail on association of vitamin D level and type 2 diabetes mellitus. The present study aims to compare serum 25-hydroxycholecalciferol (vitamin D3) level and fasting blood glucose in type 2 diabetes mellitus patients and healthy subjects and evaluate their association in both groups. Methods: This cross-sectional, observational study was done in Department of Biochemistry, Sylhet MAG Osmani Medical College, Bangladesh, between July 2015 and June 2016. The patients were selected from medicine out-patients departments (MOPD) of Sylhet MAG Osmani Medical College Hospital and Sylhet Diabetic Hospital, Bangladesh. A total of 135 study subjects were selected following convenient consecutive sampling technique. They grouped into case (Group A) i.e. 65 patients having type 2 diabetes mellitus, and control (Group B), i.e. 70 patients apparently healthy subjects (non-diabetic). Initial evaluation of the patients done by history and clinical examination was recorded in the preformed data collection sheet. Fasting blood glucose was measured by enzymatic method, while serum 25-hydroxycholecalciferol (vitamin D3) was measured by radioimmunoassay (RIA). Results: The mean age of 42.02±3.29 years in case (Group A); while 41.35±3.97 years in control (Group B). There were 33 male (50.76%) and 32 (49.23%) female in group A, while 35 (50%) male and 35 (50%) female in group B. No significant age difference was observed between the groups (p=0.284). Serum 25-hydroxycholecalciferol in cases (Group A) was 55.73±9.02 ng/ml and in controls (Group B) 53.77±10.86 ng/ ml (p=0.255). Fasting blood glucose was 161.98±62.47 mg/dl in cases (Group A) and 86.92±15.74 mg/dl in controls (Group B) (p<0.001). No correlation was found between serum 25-hydroxycholecalciferol and fasting blood glucose in any group: in type 2 diabetic patients (case group) (r=0.010, p=0.943), in healthy controls (r=0.186, p=0.122), and all study subjects together (r=0.095, p=0.268). Conclusions: Our data suggest that serum 25-hydroxycholecalciferol (vitamin D3) was within optimum level in both type 2 diabetic patients and healthy individuals. However, no correlation was found between serum 25-hydroxycholecalciferol and fasting blood glucose in any group.  

scholarly journals A prospective open labelled study of effect of vildagliptin with metformin in patients with type 2 diabetes mellitus

2019 ◽  
Vol 8 (8) ◽  
pp. 1880
Author(s):  
Lavakumar S. ◽  
Jesurun R. S.
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Body Weight ◽  
Blood Glucose ◽  
Serum Urea ◽  
Once Daily ◽  
Group A ◽  
Group B

Background: The pathophysiology of Type 2 Diabetes Mellitus (T2DM) is characterized by deficient insulin activity arising from decreased insulin secretion secondary to beta cell failure, and/or compromised insulin action in peripheral target tissues (insulin resistance).Methods: The patients attending the medicine outpatient department of tertiary care teaching hospital were enrolled in the study. Patients, who fulfilled the selection criteria, were allocated in two treatment groups. Group A was treated with metformin (Sustained release preparation) 500mg once daily and group B was treated with vildagliptin 50mg once daily. Measurement of body weight, fasting blood glucose (FPG), postprandial blood glucose (PPG), glycated haemoglobin (HbA1c), serum urea, creatinine and urine albumin/creatinine ratio was performed at the initial visit and at the end of 12 weeks of treatment.Results: Out of 84 patients screened, 74 were enrolled for the study. Of the 74 patients, 39(52.7%) were male and 35(47.3%) were female. The patients were divided into two groups (group A and group B) consisting 37 patients in each group. Out of 74 patients, 62 completed the study. Out of 12 patients who did not complete the study, 5 patients were lost during follow-up period and 7 patients discontinued treatment due to AEs. The mean age of the patients was 51 and 49years in the groups A and B respectively. There was no statistical difference in the baseline FPG, PPG, HbA1c, serum urea, serum creatinine, urine ACR and body weight between two groups.Conclusions: The study shows that metformin and vildagliptin have similar effect on glycaemic control, but vildagliptin exerts better Reno protective effect and there were no reports of serious adverse events.

Sign in / Sign up

Export Citation Format

Share Document